Novartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach